The IGF2BP family, a regulatory subunit of m6A readers, is positively correlated with PD-1 expression, demonstrating that m6A modification regulated by the IGF2BP family may have potential benefits for patients with lung adenocarcinoma treated with ICIs (133). Here, PDCD1 is linked to lung adenocarcinoma.